CALR and cancer: Guido Kroemer’s team showed that a continuous exposure to oxaliplatin (from 15 to 300 μM, depending on the cell type) induces CRT exposure, ATP and HMGB1 release by different types of cancer cells, such as murine colon cancer (CT26), fibrosarcoma (MCA205) or human bone osteosarcoma (U2OS) [6,31,33,75].